Publications by authors named "Aaron Polliack"

Claim this Profile
T
Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions.
Stefano Molica, Constantine Tam, David Allsup, Aaron Polliack

Hematol Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option.
Stefano Molica, Constantine Tam, David Allsup, Aaron Polliack

Cancers (Basel)· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The net clinical benefit of targeted agents in the upfront treatment of elderly/unfit chronic lymphocytic leukemia patients: Results of network meta-analysis.
Stefano Molica, David Allsup, Aaron Polliack, Diana Giannarelli

Eur J Haematol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The enigma of LAG3 receptor in hematological malignancies.
Natalia Kreiniz, Aaron Polliack, Tamar Tadmor

Leuk Lymphoma· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia.
Farhad Ravandi, Robert J Kreitman, Enrico Tiacci, Leslie Andritsos, Versha Banerji, Aaron Polliack

Blood Cancer J· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current perspectives regarding SARS-CoV-2 vaccination in chronic lymphocytic leukemia.
Stefano Molica, Constantine Tam, Aaron Polliack

Hematol Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adherence to ibrutinib remains an unmet clinical need in chronic lymphocytic leukemia.
Stefano Molica, David John Allsup, Aaron Polliack

Leuk Lymphoma· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is ibrutinib the gold standard for therapy - naive elderly patients with CLL?
Estella Matutes, Aaron Polliack

Leuk Lymphoma· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.
Ohad Benjamini, Lior Rokach, Gilad Itchaki, Andrei Braester, Lev Shvidel, Aaron Polliack

Haematologica· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination.
Yair Herishanu, Galia Rahav, Shai Levi, Andrei Braester, Gilad Itchaki, Aaron Polliack

Blood· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A perspective on prognostic models in chronic lymphocytic leukemia in the era of targeted agents.
Stefano Molica, John F Seymour, Aaron Polliack

Hematol Oncol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials.
Fortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, Francesca Romana Mauro, Gianluigi Reda, Aaron Polliack

Am J Hematol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases.
Fortunato Morabito, Giovanni Del Poeta, Francesca Romana Mauro, Gianluigi Reda, Paolo Sportoletti, Aaron Polliack

Am J Hematol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hairy cell leukemia and COVID-19 adaptation of treatment guidelines.
Michael Grever, Leslie Andritsos, Versha Banerji, Jacqueline C Barrientos, Seema Bhat, Aaron Polliack

Leukemia· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multifocal osteolytic lesions in hairy cell leukemia-the importance of PET/CT in diagnosis and assessment.
Pawel Robak, Dorota Jesionek-Kupnicka, Piotr Kupnicki, Aaron Polliack, Tadeusz Robak

Ann Hematol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemia.
Stefano Molica, David Allsup, Valentina Gianfelici, Luciano Levato, Vincenzo Aiello, Aaron Polliack

Expert Opin Investig Drugs· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study.
Fortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, Francesca Romana Mauro, Gianluigi Reda, Aaron Polliack

Am J Hematol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting.
Stefania Bettelli, Raffaella Marcheselli, Samantha Pozzi, Luigi Marcheselli, Robel Papotti, Aaron Polliack

Leuk Res· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic lymphoproliferative disorders and secondary cancers in the era of purine analogues and beyond.
Sean Harrop, Aaron Polliack, Constantine S Tam

Leuk Lymphoma· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases.
Fortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, Francesca Romana Mauro, Gianluigi Reda, Aaron Polliack

Eur J Haematol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Demyelinating brain lesions developing in a patient with chronic lymphocytic leukemia shortly after treatment with a fludarabine containing regimen.
Natalia Kreiniz, Maya Garty-Ofir, Jacob Bejar, Aaron Polliack, Tamar Tadmor

Hematol Oncol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study.
Massimo Gentile, Fortunato Morabito, Giovanni Del Poeta, Francesca Romana Mauro, Gianluigi Reda, Aaron Polliack

Leukemia· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone lesions in hairy cell leukemia: Diagnosis and treatment.
Pawel Robak, Dorota Jesionek-Kupnicka, Piotr Kupnicki, Aaron Polliack, Tadeusz Robak

Eur J Haematol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma.
Raffaella Marcheselli, Alessia Bari, Tamar Tadmor, Luigi Marcheselli, Maria Christina Cox, Aaron Polliack

Hematol Oncol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group.
Yair Herishanu, Adir Shaulov, Riva Fineman, Sandra Bašić-Kinda, Ariel Aviv, Aaron Polliack

Am J Hematol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis